Antibody-Hapten Complexes for Imaging
The tumor uptake of covalently-radiolabeled monoclonal antibodies and their fragments is directly related to the integral of blood concentration over time, the highest tumor concentrations being obtained with whole antibody which has the longest biological half-life in the plasma (1,2,3). Higher tumor to background ratios can be obtained with F(ab′)2 or Fab fragments that disappear more rapidly than whole antibody from the blood but only at the cost of a lower absolute tumor concentration (1,2). Tumor concentration of whole antibody reaches a maximum in approximately one or two days but the major fraction continues to circulate for many days after due to the slow excretion of covalently labeled proteins. This prolonged retention of activity adds a large amount of useless radiation exposure to normal tissue, especially liver, spleen, and bone marrow.
KeywordsPermeability Lymphoma EDTA Recombination Radionuclide
Unable to display preview. Download preview PDF.
- 2.R. L. Wahl, C. W. Parker, and G. W. Philpott, Improved radioimaging and tumor localization with monoclonal F(ab)2, J. Nuc1. Med. 24:316–325 (1983).Google Scholar
- 3.W. B. Nelp, J. F. Eary, P. Beaumier, K. A. Krohn, I. Hellstrom, and K. E. Hellstrom, Antibody deposition in tumor in relation to blood clearance using a nephrectomized mouse model, J. Nucl. Med. 26:67 (1985). Abstract.Google Scholar
- 5.D. A. Goodwin, C. F. Meares, W. Chaovapong, M. McTigue, and M. J. McCall, Bifunctional chelates with a haptenic function bind reversibly to monoclonal antibody WC3A11 for radiopharmaceutical delivery, J. Nucl. Med. 27:938 (1986). Abstract.Google Scholar
- 6.D. A. Goodwin, C. F. Meares, M. McTigue, and G. S. David, Monoclonal antibody hapten radiopharmaceutical delivery, Nucl. Med. Comm. (In press).Google Scholar
- 7.D. A. Goodwin, S. I. Smith, C. F. Meares, G. S. David, M. McTigue, and R. A. Finston, Chelate chase of radiopharmaceuticals reversibly bound to monoclonal antibodies improves dosimetry, Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge TN, November 5–8, 1985, Proc. Conf-851113-ORAV, 1986, pp.477–492.Google Scholar
- 8.S. W. Burcheil and B. A. Rhodes, eds., “Radioimmunoimaging and Radioimmunotherapy,” Elsevier, New York (1983).Google Scholar
- 14.M. K. Haseman, D. A. Goodwin, C. F. Meares, M. S. Kaminski, T. G. Wensel, M. J. McCall, and R. Levy, Metabolizable In-111 chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice, Eur. J. Nucl. Med., Submitted.Google Scholar
- 15.D. A. Goodwin, C. F. Meares, M. McTigue, and M. R. Stone, Hapten monoclonal antibody complexes as drug carrier systems, Amer. Chem. Soc. Annual National Meeting, Miami Beach, Florida, 48 (1985). Abstract.Google Scholar
- 16.D. A. Goodwin, C. F. Meares, G. S. David, M. McTigue, M. J. McCall, J. M. Frincke, M. R. Stone, R. M. Bartholomew, and J. P. Leung, Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals, Int. J. Nucl. Med. Biol. 13:383–391 (1986).Google Scholar
- 21.D. A. Goodwin, C. F. Meares, C. I. Diamanti et al., Biological properties of molecules labelled with metal ions using bifunctional chelates, in: “Medical Radionuclide Imaging,” IAEA, Vienna, 2:61–69 (1976).Google Scholar